Avita Medical | MedPath

AVITA Medical Reports 67% Revenue Growth in Q1 2025, Expands Product Portfolio

a month ago

• AVITA Medical reported Q1 2025 commercial revenue of $18.5 million, representing a 67% increase compared to the same period in 2024, with a strong gross profit margin of 84.7%. • The company has transformed from a single-product burn-focused company to a multi-product platform with the launch of RECELL GO mini in February and nationwide rollout of Cohealyx in April 2025. • AVITA Medical reaffirmed its 2025 guidance, projecting full-year commercial revenue between $100-106 million, with expectations to generate free cash flow in the second half of 2025 and achieve GAAP profitability by Q4.

AVITA Medical to Present New Clinical Data on PermeaDerm for Burn and Wound Management at ABA 2025

a month ago

• New clinical data demonstrates PermeaDerm's effectiveness as a temporary wound coverage solution in burn management, offering an alternative to higher-priced cadaver skin while preserving wound integrity. • A randomized multicenter trial shows PermeaDerm reduces dressing change frequency compared to traditional silver-based dressings, with its transparency enabling continuous wound monitoring. • AVITA Medical continues to expand its acute wound care portfolio, which includes the FDA-approved RECELL System for thermal burns and full-thickness skin defects, alongside Cohealyx and PermeaDerm products.

AVITA Medical Launches Cohealyx: New Collagen-Based Dermal Matrix Accelerates Wound Healing

2 months ago

• AVITA Medical has commercially launched Cohealyx, a collagen-based dermal matrix co-developed with Regenity Biosciences, designed to facilitate cellular migration and revascularization for wound healing. • Pre-clinical studies demonstrated that Cohealyx prepares wounds for grafting faster than leading competitors, potentially reducing hospital stays for patients with full-thickness acute wounds. • The product expands AVITA's therapeutic wound care portfolio, complementing its FDA-approved RECELL System and PermeaDerm, creating an integrated approach to the two-stage standard of care for full-thickness wounds.

New Report Reveals Critical Insights into Clinical-Stage Pharma Partnerships from 2020-2025

2 months ago

• A comprehensive new industry report analyzes over 1,670 clinical-stage partnering agreements in pharma and biotech from 2020-2025, providing unprecedented access to deal structures and financial terms. • The report reveals detailed intelligence on how licensing agreements typically grant exclusive rights across Phase I-III trials, with multi-component structures involving collaborative R&D and commercialization strategies. • Business development professionals can now access actual contract documents and payment triggers often missing from press releases, enabling more effective negotiation strategies and competitive deal structuring.

AVITA Medical's RECELL GO Mini Receives FDA Approval for Smaller Wound Treatment

5 months ago

• AVITA Medical's RECELL GO mini has been approved by the FDA for treating smaller full-thickness skin defects, addressing a critical need in wound care. • The RECELL GO mini cartridge treats wounds up to 480 square centimeters, offering a resource-efficient option compared to the standard RECELL GO cartridge. • AVITA Medical plans to launch RECELL GO mini in trauma and burn centers during Q1 2025, expanding the accessibility of RECELL technology. • The approval strengthens AVITA Medical's strategy to broaden its impact on patient care by providing clinicians with tailored solutions for diverse wound sizes.

FDA Approves AVITA Medical's RECELL System for Vitiligo Skin Repigmentation

2 years ago

AVITA Medical has received FDA approval for its RECELL System, a groundbreaking treatment for repigmentation in patients with stable vitiligo. This one-time, point-of-care treatment utilizes autologous skin cells to safely and effectively restore pigmentation, marking a significant advancement in vitiligo care.